BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:With the entire world's attention focused firmly on pulmonary 
 fibrosis in the wake of COVID19 and the landmark INBUILD study dramatical
 ly overhauling the ILD drug development landscape\, biopharma are finally
  on the cusp of developing and disseminating life-changing therapeutics f
 or patients suffering with interstitial lung disease.\n\nBuilt from metic
 ulous research with a faculty of world-renowned lung fibrosis heavyweight
 s including Boehringer Ingelheim\, Novartis\, Roche\, Abbvie\, AdAlta and
  more\, the inaugural Interstitial Lung Disease Drug Development Summit i
 s the only industry focused forum giving you access to the ground-breakin
 g research and radical insights you need to re-energize and revolutionize
  your drug development strategy against the next pulmonary fibrosis front
 ier.\n\nAcross 3 unique days\, you will discover how to optimize combinat
 ion regimes to treat fibrotic lungs to achieve success in your clinical t
 rials\, analyze lessons learned from IPF trials to accelerate progress fo
 r your novel pulmonary fibrosis therapies and hear how you can utilize th
 e latest research on ILD mechanisms to streamline your drug development s
 trategy and treat SSc-ILD\, RA-ILD\, Scleroderma\, Sjogren's Syndrome\, S
 arcoidosis and more.\n\nDon't miss the opportunity to join 50+ senior res
 piratory and fibrosis stakeholders at this unique and comprehensive digit
 al event dedicated to advancing and optimizing your anti-fibrotic drug de
 velopment beyond IPF\n
DTEND:20210429T150000
DTSTAMP:20260307T151616Z
DTSTART:20210427T090000
LOCATION:Online\, Online\, \,
SEQUENCE:0
SUMMARY:With the entire world's attention focused firmly on pulmonary fibr
 osis in the wake of COVID19 and the landmark INBUILD study dramatically o
 verhauli...
UID:5343d08e-f783-4e11-9f55-158b698ccb96
END:VEVENT
END:VCALENDAR